New insights into the pathogenesis of cutaneous autoimmune disorders

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 2, 2012, Pages 165-170

  Chiricozzi, Andrea ^a,b   Zhang, S ^c   Dattola, A ^a   Cannizzaro, M V ^a   Gabellini, M ^a   Chimenti, S ^a   Nistico S P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 17; Lupus erythematosus; Pemphigoid; Pemphigus; Scleroderma; Th17

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23;

AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DERMATOMYOSITIS; HUMAN; INFLAMMATION; LYMPHOCYTIC INFILTRATION; PATHOGENESIS; PEMPHIGUS VULGARIS; REVIEW; SCLERODERMA; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEMPHIGOID, BULLOUS; PEMPHIGUS; SCLERODERMA, SYSTEMIC; SKIN DISEASES; TH17 CELLS;

EID: 84865033009     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18:349-56.
2. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. Integrative responses to TL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131(3):677-87.
3. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159(5): 1092-102.
4. Laan M, Cui ZH, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh BE, Linden A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162 (4):2347-52. (Pubitemid 29288861)
5. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226:57-79.
6. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175(1):404-12. (Pubitemid 40884344)
7. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-I expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 162:494-502. (Pubitemid 29018959)
8. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183(6):2593-603. (Pubitemid 26193037)
9. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C, Moretto M, Khan IA. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005; 73:617-21. (Pubitemid 40041158)
10. Ye P, Rodriguez FH, Kanály S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194 (4):519-27. (Pubitemid 32835046)
11. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190(3):624-31. (Pubitemid 38982105)
12. Chao CC, Chen SJ, Adamopoulos IE, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011; 44(3):243-52.
13. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924):744-8. (Pubitemid 36227625)
14. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201(2):233-40. (Pubitemid 40189432)
15. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA and van den Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen- induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-59. (Pubitemid 38198849)
16. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52(l):65-70. (Pubitemid 36020767)
17. Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-6.
18. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8(6):458-66. (Pubitemid 351733422)
19. Begovich AB, Chang M, Caillier SJ, Lew D, Catanese JJ, Wang J, Häuser SL, Oksenberg JR. The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. Hum Immunol 2007; 68(11):934-7. (Pubitemid 350235722)
20. Ca M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80 (2):273-90. (Pubitemid 46175676)
21. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41(2): 199-204.
22. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9(8):589-93.
23. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5(2): 101-4. (Pubitemid 29186827)
24. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31:205-10. (Pubitemid 34971876)
25. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of ThI and ThI7 T cells. J Invest Dermatol 2008; 128(5):1207-11. (Pubitemid 351543220)
26. Holgate ST.Pathogenesis of asthma. Clin Exp Allergy 2008; 38(6):872-97.
27. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001;357:1027-32. (Pubitemid 32285401)
28. Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH. Disturbed Th1, Th2, Th17 and T (reg) balance in patients with systemic lupus erythematosus. Clin Immunol 2011; 141(2): 197-204.
29. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10(7):778-85.
30. Tanasescu C, Balanescu E, Balanescu P, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010; 21 (3):202-7.
31. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43 (11):2455-63.
32. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009; 68 (4):604-6.
33. Connolly MK. Systemic Sclerosis (Scleroderma) and Related Disorders. Chapter 44 in Dermatology 2nd Edition, Bolognia JL, Jorizzo JL, Rapini RP. 1998; p. 1319-44.
34. Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martínez-Reyes C, Díaz-Zamudio M, Llorente L. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 2011 Jul 26. [Epub ahead of print]
35. Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007; 3(12):682-3. (Pubitemid 350187010)
36. Katz Y, Nadiv O, Beer Y Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum 2001; 44 (9):2176-84. (Pubitemid 33644063)
37. Tournadre A, Miossec P. Interleukin-17 in Inflammatory Myopathies. Curr Rheumatol Rep 2012; 14(3):252-6.
38. Tournadre A, Porcherot M, Chérin P, Marie I, Hachulla E, Miossec P. ThI and Thl7 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009; 46(3):297-301.
39. Arakawa M, Dainichi T, Ishii N, et al. Lesionai Thl7 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 2011; 20(12): 1022-4.
40. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesionai Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sei 2009; 53 (3):228-31.